IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study

被引：0

作者：

Shu, J. ^{[1
]}

Zhu, T. ^{[2
]}

Huang, Y. ^{[3
]}

Xu, Q. ^{[4
]}

Guo, R. ^{[5
]}

Liu, H. ^{[6
]}

Zhao, H. ^{[7
]}

Zhu, L. ^{[8
]}

Wang, X. ^{[9
]}

Xu, X. ^{[10
]}

Cheng, W. ^{[11
]}

Tang, J. ^{[12
]}

Zhu, Q. ^{[13
]}

Chen, X. ^{[14
]}

An, R. ^{[15
]}

Gao, J. ^{[16
]}

Li, G. ^{[17
]}

Zhang, Z. ^{[18
]}

Zhou, H. ^{[19
]}

Zhou, Q. ^{[20
]}

机构：

[1] Chongqing Univ, Affiliated Canc Hosp, Dept Gynecol, Chongqing, Peoples R China

[2] Zhejiang Canc Hosp, Gynaecol Oncol, Hangzhou, Peoples R China

[3] Hubei Canc Hosp, Gynecol Oncol, Wuhan, Peoples R China

[4] Fujian Prov Canc Hosp, Dept Gynecol Oncol, Fuzhou, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Gynaecol Oncol Dept, Zhengzhou, Peoples R China

[6] Gansu Prov Hosp, Gynecol Dept, Lanzhou, Peoples R China

[7] Shanxi Canc Hosp, Gynaecol Oncol Dept, Taiyuan, Peoples R China

[8] Nanjing Univ, Oncol Dept, Nanjing Drum Tower Hosp, Sch Med, Nanjing, Peoples R China

[9] Xuzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[10] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Gynecol Oncol, Beijing, Peoples R China

[11] Jiangsu Prov Hosp, Gynecol Dept, Nanjing, Peoples R China

[12] Hunan Canc Hosp, Gynecol Oncol, Changsha, Peoples R China

[13] Jiangxi Maternal & Child Hlth Care Hosp, Dept Oncol, Nanchang, Jiangxi, Peoples R China

[14] Fudan Univ, Dept Oncol, Jiangxi Maternal & Child Hlth Care Hosp, Shanghai, Peoples R China

[15] Xi An Jiao Tong Univ, Affiliated Hosp 1, Gynecol Dept, Xian, Peoples R China

[16] Jiangxi Canc Hosp, Dept Gynecol Oncol, Nanchang, Jiangxi, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gynecol & Oncol, Union, NJ USA

[18] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China

[19] Innovent Biol Suzhou Co Ltd, Med Oncol, Suzhou, Peoples R China

[20] Chongqing Univ, Affiliated Canc Hosp, Gynecol Oncol, Chongqing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

720MO

引用

页码：S551 / S551

页数：1

共 50 条

[1] IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Lemech, C.
Sun, Y.
Nagrial, A.
Wu, X.
Morris, M.
Ning, F.
Yang, J.
Pan, Y.
Cai, J.
Lu, P.
Zhang, T.
Qiu, F.
Hu, C.
Zhang, M.
Liu, Z.
Han, G.
Nie, J.
Teng, C.
Zhou, H.
Day, D.
ANNALS OF ONCOLOGY, 2024, 35 : S360 - S360
[2] Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Gong, J.
Lemech, C.
Day, D.
Shan, J.
Morris, M.
Nagrial, A.
Chen, M.
Huang, X.
Zong, H.
Wang, N.
Yang, Y.
Yi, T.
Li, W.
Zhuang, Z.
Li, Z.
Liu, Z.
Luo, Y.
Zhang, Y.
Zhou, H.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S467 - S468
[3] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
Lopez, Diana M.
Barve, Minal
Wang, Judy
Bullock, Andrea J.
Pectasides, Eirini
Vaishampayan, Ulka
Spira, Alexander I.
Ulahannan, Susanna
Patnaik, Amita
Sanborn, Rachel E.
Cicic, Dragan
Ang, Qiuqing
Bergonio, Gregory
Ahnert, Jordi Rodon
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[4] Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study
Yu, X.
Zhang, J.
Liu, J. J.
Yang, J.
Yue, J.
Sun, Y.
Pan, Y.
Sun, M. L.
Qin, Y.
Shen, L.
Song, R.
Ruan, J.
Zhou, A.
Mou, Y.
Aghmesheh, M.
Morris, M.
Yu, X.
Zhao, X.
Chen, M.
Tazbirkova, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
[5] ABBV-400, a c-Met proteinetargeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Strickler, J. H.
Raimbourg, J.
Ghiringhelli, F.
Cohen, J. E.
Kitagawa, C.
Sharma, M. R.
Lee, K. H.
De Miguel, M.
Hunter, Z. N.
Burns, M.
Li, R. R.
Rudraganguly, N.
de Almeida, C. Biesdorf
Freise, K. J.
Blaney, M. E.
Morrison-Thiele, G.
Aristide, M. R. Neagu
Kuboki, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S895 - S896
[6] Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma
Sznol, M.
Hamid, O.
Hwu, P.
Kluger, H.
Hawthorne, T.
Crowley, E.
Simantov, R.
Pavlick, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[7] A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Zhou, Chenfei
Wang, Bin
Teng, Christina
Yang, Hui
Piha-Paul, Sarina A.
Richardson, Gary
Malalasekera, Ashanya
Sun, Yajun
Wang, Wei
Liu, Jieqiong
Shi, Yan
Zhan, Xianbao
Lemech, Charlotte
JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
[8] A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.
Kim, Richard D.
Cleary, James M.
Leal, Alexis Diane
Parikh, Aparna Raj
Ryan, David P.
Wang, Shining
Bahamon, Brittany
Gupta, Neeraj
Moss, Aaron
Pye, Joanna
Miao, Harry H.
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
Li, Weisong
Zheng, Chao
Xu, Xi
Xia, Yujie
Zhang, Kai
Huang, Ao
Zhang, Xinyu
Zheng, Yong
Chen, Guofang
Zhang, Shuyong
CELLULAR & MOLECULAR BIOLOGY LETTERS, 2024, 29 (01)
[10] Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors
Ma, Dangshe
Narayanan, Bitha
Marquette, Kim
Graziani, Edmund
Loganzo, Frank
Charati, Manoj
Prashad, Nadira
Tumey, Nathan
Golas, Jon
Hosselet, Christine
Hu, George
Barletta, Frank
Betts, Alison
Lucas, Judy
O'Donnell, Chris
Tchistiakova, Lioudmila
Gerber, Hans-Peter
Sapra, Puja
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →